A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. [electronic resource]
Producer: 20120907Description: 1121-1129 p. digitalISSN:- 1569-8041
- Adult
- Algorithms
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Breast Neoplasms -- drug therapy
- Carcinoma -- drug therapy
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Docetaxel
- Dose-Response Relationship, Drug
- Epirubicin -- administration & dosage
- Female
- Humans
- Italy
- Lymph Nodes -- pathology
- Lymphatic Metastasis
- Middle Aged
- Prospective Studies
- Survival Analysis
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.